MGI, a division of BGI Group, announced that Micromon Genomics is the first Australian commercial user of its high-throughput genetic sequencer MGISEQ-2000. Monash University’s Micromon Genomics, a next-generation sequencing facility located in the university’s Biomedical precinct at the Clayton campus in Melbourne, provides sequencing services to Australian researchers, including DNA, RNA, single cell and customised applications. “This instrument precisely fits our yield requirements, giving us the flexibility and scope to complete both small and large projects, without the necessity to queue large numbers of samples before commencing sequencing runs,” Micromon Genomics’ NGS Manager Mr. Scott Coutts said. “Data quality is equal to or better than the data we currently generate on alternative platforms, as well as bringing about substantial service price reductions.” MGI has a strong local support team based in Brisbane providing commercial support, technical training and after-sale services to Australia and New Zealand. To provide better product and service for users in the region, MGI authorised Decode Science as the distributor for next generation sequencers and related products. MGI and DS jointly provide after sales applications and service support to new and existing units in the region, utilising MGI's dedicated local support team. MGI instruments are gaining more recognition from local scientists and researchers. MGI has delivered over 1,000 sequencers to more than 300 users in 16 countries worldwide.
Micromon is a not-for-profit facility located in the Biomedical precinct at Monash University, Melbourne, Australia. As a specialist facility, Micromon offers expertise in DNA and RNA technologies where Sanger long-read sequencing and Next-Generation short-read sequencing form the key services, along with allied technologies. With more than 35 years of experience, Micromon has a long history of excellent project design and management, and a strong focus on personalised customer service and support.